# Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

> **NCT04460235** · PHASE4 · RECRUITING · sponsor: **Poitiers University Hospital** · enrollment: 160 (estimated)

## Conditions studied

- Vaccine
- Streptococcus Pneumoniae
- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** Prevenar 13 + Pneumovax 23
- **BIOLOGICAL:** PREVENAR20

## Key facts

- **NCT ID:** NCT04460235
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-07
- **Primary completion:** 2026-12
- **Final completion:** 2027-11
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460235, "Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04460235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*